GSK· @GSK · X·· 2026-08-24精选AI 评分62
AI 导读
葛兰素史克宣布日本成为首个批准其慢性乙肝（CHB）新疗法的国家，称这是肝病创新领域的重要里程碑。GSK指出，慢性乙肝仍是全球肝癌的主要病因之一，此次获批体现其在肝病研究上的持续投入。
推荐理由
日本成为首个批准该慢性乙肝新疗法的国家，可据此观察乙肝治疗与肝癌预防的监管进展。
正文
#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB), marking an important milestone in liver disease innovation.
CHB remains a leading cause of liver cancer worldwide. This approval reflects continued commitment to progress in liver disease research.
Learn more: https://gsk.to/4wNSLxB
来源：GSK · x.com